On July 28, 2020 NeuPharma, a Suzhou biopharma, reported that dosed the first patient in a Phase II trial of RX108 in patients of recurrent/metastatic head and neck squamous cell carcinoma (Press release, NeuPharma, JUL 28, 2020, View Source [SID1234562538]). RX108 is a novel small-molecule inhibitor that targets sodium-potassium adenosine triphosphatase (Na + /K + -ATPase), an important signal transducer and ion transporter. Currently, RX108 is in multiple clinical trials in China and the US for several different types of tumors. Neupharma is developing four molecules for oncology and one for neurodegeneration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!